Skip to Main Content
Table 1—

Baseline demographic and clinical characteristics of each study group

CharacteristicsMetformin
Placebo
Run inRandomizationRun inRandomization
n 14
 
 13
 
 
Age (years) 15.7 ± 1.9 15.9 ± 1.9 15.9 ± 1.7 16 ± 1.7 
Sex (F/M) 8/6
 
 6/7
 
 
Duration of diabetes (years) 9.7 ± 4.4 9.9 ± 4.4 6.9 ± 3.8 7 ± 3.8 
Weight (kg) 62.9 ± 13.7 63.3 ± 13.6 71.2 ± 11.7 71.6 ± 11.7 
BMI (kg/m222.7 ± 4.1 22.8 ± 4.2 25.4 ± 2.9 25.7 ± 2.9 
Pubertal status (Tanner2–3/Tanner4–55/9
 
 5/8
 
 
HbA1c (%) 9.4 ± 1 9.3 ± 1.4 8.9 ± 0.8 8.6 ± 0.8 
Insulin dosage (units · kg−1 · day−11.2 ± 0.2 1.21 ± 0.3 1.3 ± 0.2 1.28 ± 0.19 
SI (× 10−4 · min−1 · μU−1 · ml−11.7 (CI 1.0–2.6)
 
 1.1 (CI 0.6–2.2)
 
 
CharacteristicsMetformin
Placebo
Run inRandomizationRun inRandomization
n 14
 
 13
 
 
Age (years) 15.7 ± 1.9 15.9 ± 1.9 15.9 ± 1.7 16 ± 1.7 
Sex (F/M) 8/6
 
 6/7
 
 
Duration of diabetes (years) 9.7 ± 4.4 9.9 ± 4.4 6.9 ± 3.8 7 ± 3.8 
Weight (kg) 62.9 ± 13.7 63.3 ± 13.6 71.2 ± 11.7 71.6 ± 11.7 
BMI (kg/m222.7 ± 4.1 22.8 ± 4.2 25.4 ± 2.9 25.7 ± 2.9 
Pubertal status (Tanner2–3/Tanner4–55/9
 
 5/8
 
 
HbA1c (%) 9.4 ± 1 9.3 ± 1.4 8.9 ± 0.8 8.6 ± 0.8 
Insulin dosage (units · kg−1 · day−11.2 ± 0.2 1.21 ± 0.3 1.3 ± 0.2 1.28 ± 0.19 
SI (× 10−4 · min−1 · μU−1 · ml−11.7 (CI 1.0–2.6)
 
 1.1 (CI 0.6–2.2)
 
 

Data are means ± SD, except SI, which is expressed as geometric mean and 95% CI.

Close Modal

or Create an Account

Close Modal
Close Modal